**Previous inclusion criteria**

Previous inclusion criteria from 30/07/2020 to 28/09/2020:

1. Adults aged 18-55 years (groups 4, 5, 6 and 11)

2. Adults aged 56-69 years (groups 1, 7 and 9)

3. Adults aged 70 years and older (groups 2, 8 and 10)

4. Children aged 5-12 years inclusive (group 3)

5. Able and willing (in the Investigator’s opinion) to comply with all study requirements

6. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures

7. For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination

8. Agreement to refrain from blood donation during the course of the study

9. Provide written informed consent

10. Parent/guardian provides informed consent

Previous inclusion criteria from 15/06/2020 to 24/06/2020:

1. Adults aged 18 years or older (groups 4 and 6); aged 18-55 years (group 5)

2. Adults aged 56 years or older (groups 1 and 2)

3. Children aged 5-12 years inclusive (group 3)

4. Able and willing (in the Investigator’s opinion) to comply with all study requirements

5. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures

6. For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination

7. Agreement to refrain from blood donation during the course of the study

8. Provide written informed consent

9. Parent/guardian provides informed consent

\_\_\_\_\_

Previous inclusion criteria as of 22/05/2020:

1. Adults aged 18 years or older (group 4); aged 18-55 years (group 5)

2. Adults aged 56 years or older (groups 1 and 2)

3. Children aged 5-12 years inclusive (group 3)

4. Able and willing (in the Investigator’s opinion) to comply with all study requirements

5. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures

6. For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination

7. Agreement to refrain from blood donation during the course of the study

8. Provide written informed consent

9. Parent/guardian provides informed consent

\_\_\_\_\_

Previous inclusion criteria:

1. Adults aged 18 or older (group 4)

2. Adults aged 56 or older (groups 1 and 2)

3. Children aged 5-12 inclusive (group 3)

4. Able and willing (in the Investigator’s opinion) to comply with all study requirements

5. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures

6. For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination

7. Agreement to refrain from blood donation during the course of the study

8. Provide written informed consent

9. Parent/guardian provides informed consent

**Previous exclusion criteria**

Previous exclusion criteria from 25/08/2020 to 28/09/2020:

1. Participation in COVID-19 prophylactic drug trials for the duration of the study

Note: Participation in COVID-19 treatment trials is allowed in the event of hospitalisation due to COVID-19. The COV002 study team should be informed as soon as possible

2. Participation in SARS-CoV-2 serological surveys where participants are informed of their serostatus for the duration of the study

Note: Disclosure of serostatus post enrolment may accidently unblind participants to group allocation. Participation in COV002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys

3. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination, with the exception of the seasonal influenza vaccination. Participants will be encouraged to receive this vaccination at least 7 days before or after their study vaccine

4. Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). This exclusion criteria will not apply to group 11, as recruitment will be targeted at those volunteers who previously received a ChAdOx1 vectored vaccine.

5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

6. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days)

7. History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY

8. Any history of angioedema

9. Any history of anaphylaxis

10. Pregnancy, lactation or willingness/intention to become pregnant during the study

11. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

12. History of serious psychiatric condition likely to affect participation in the study

13. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture

14: Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)

15. Suspected or known current alcohol or drug dependency

16. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

17. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

18. History of laboratory confirmed COVID-19

18.1 Seropositivity to SARS-CoV-2 before enrolment (except groups 5d, 9 and,10 and 11)

Additional exclusion criteria for Groups 4, 6, 9 and 10:

19. History of allergic disease or reactions likely to be exacerbated by paracetamol. Note: Caution should be taken when recommending paracetamol to adults who already take paracetamol chronically

Additional exclusion criteria for Group 3:

20. Chronic medical conditions such as chronic lung disease, chronic liver disease, chronic renal failure, chronic heart disease, congenital genetic syndromes (e.g. Trisomy 21)

21. Fulfil any of the contraindications to vaccination as specified in The Green Book

Previous exclusion criteria as of 22/05/2020:

1. Participation in COVID-19 prophylactic drug trials for the duration of the study

Note: Participation in COVID-19 treatment trials is allowed in the event of hospitalisation due to COVID-19. The COV002 study team should be informed as soon as possible

2. Participation in SARS-CoV-2 serological surveys where participants are informed of their serostatus for the duration of the study

Note: Disclosure of serostatus post enrolment may accidently unblind participants to group allocation. Participation in COV002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys

3. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination

4. Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines)

5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

6. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days)

7. History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY

8. Any history of angioedema

9. Any history of anaphylaxis

10. Pregnancy, lactation or willingness/intention to become pregnant during the study

11. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

12. History of serious psychiatric condition likely to affect participation in the study

13. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture

14: Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)

15. Suspected or known current alcohol or drug dependency

16. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

17. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

18. History of laboratory confirmed COVID-19

19. Seropositivity to SARS-CoV-2 before enrolment

Additional Exclusion criteria to Group 4:

20. History of allergic disease or reactions likely to be exacerbated by Paracetamol

Additional Exclusion Criteria to Group 3:

21. Chronic medical conditions such as chronic lung disease, chronic liver disease, chronic renal failure, chronic heart disease, congenital genetic syndromes (e.g. Trisomy 21)

22. Fulfil any of the contraindications to vaccination as specified in The Green Book

\_\_\_\_\_

Previous exclusion criteria:

1. Current or planned participation in other clinical trial of an investigational medicinal product

2. Prior receipt of any vaccines (licensed or investigational) ≤30 days before enrolment

3. Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination

4. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines)

5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and chronic use (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed)

7. History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY

8. Any history of hereditary angioedema or idiopathic angioedema

9. Any history of anaphylaxis

10. Pregnancy, lactation or willingness/intention to become pregnant during the study

11. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

12. History of serious psychiatric condition likely to affect participation in the study

13. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture

14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week

15. Suspected or known injecting drug abuse in the 5 years preceding enrolment

16. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

17. History of laboratory-confirmed COVID-19

18. New onset of fever or a cough or shortness of breath since February 2020

19. Those who have been at high risk of exposure before enrolment, including but not limited to: close contacts of confirmed COVID-19 cases, anyone who had to self-isolate as a result of a symptomatic household member, frontline healthcare professionals working in A&E, ICU and other higher-risk areas and significant exposure associated with travel abroad to high incidence areas since January 2020

20. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)

Additional exclusion criteria for Groups 1 and 2:

1. Chronic respiratory disease, including asthma

2. Severe and/or uncontrolled cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild well-controlled comorbidities are allowed)

3. Seriously overweight (BMI ≥40 kg/m²)

4. History of auto-immune disease

Additional exclusion criteria for Group 3:

1. Chronic medical conditions such as chronic lung disease, chronic liver disease, chronic renal failure, chronic heart disease, congenital genetic syndromes (e.g. Trisomy 21)

2. Fulfil any of the contraindications to vaccination as specified in The Green Book